ClinicalTrials.gg
Active, not recruitingNCT06137261SCOR(hf)EUpdated Sep 3, 2026

Screening Adults With Obesity to Reduce Heart Failure Events

An interventional study of Screening for heart failure in Obesity and Heart Failure, sponsored by Franciscus Gasthuis. Active, not recruiting at 1 site in Netherlands. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Franciscus Gasthuis · Not applicable, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.

Planned enrollment
34th of 211
420 · median 58
Started
2024
with 9 others
No phase
128 of 248
17 open now
Primary completion
2026-12
later than 10 of 54 live
Registered
193rd of 248
by date

Among the 248 studies in Obesity with a site in Netherlands, this one is the 34th largest by planned enrollment of the 211 interventional ones that give a count, is one of 10 that started in 2024, is one of 128 with no phase, reaches primary completion later than 10 of the 54 other live ones, and was the 193rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Obesity with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale:

Obesity prevalence in Dutch adults increased to 14.2% in 2020. Obesity is strongly associated with cardiovascular disease, especially heart failure (HF). HF is a serious condition with significant morbidity and mortality. HF in people with obesity often remains undetected for a relatively long time, because symptoms are attributed to the obesity and not to possible HF. As a result, individuals seek help late for already advanced HF. Screening may reveal HF risk factors or a HF diagnosis. Early treatment initiation will improve prognosis, both in terms of quality of life and morbidity and mortality.

Objective:

To investigate whether active screening for early signs of HF and its risk factors in adults with obesity without known heart disease improves clinical outcome.

Study design:

Investigator driven, not blinded, randomized controlled superiority trial.

Study population:

Consecutive individuals with obesity (body mass index ≥30 kg/m2) ≥ 45 years, without known cardiac disease, who sign up to participate in a Combined Lifestyle Intervention program, will be recruited.

Intervention: Participant randomized to the intervention will undergo an active screening on HF and its risk factors, using anamnesis, physical examination, an electrocardiogram, blood tests and an echocardiogram.

Main study parameters/endpoints:

The main study endpoint is a combined endpoint of left ventricular dysfunction and/or HF.

Read the detailed description

INTRODUCTION AND RATIONALE

Obesity (body mass index (BMI) ≥30 kg/m2) prevalence in Dutch adults increased to 14.2% in 2020. In Rotterdam this percentage is even higher. Obesity is strongly associated with cardiovascular disease, especially heart failure (HF). Unpublished data of our research group show that 20% of subjects with obesity without known cardiac disease who are evaluated for bariatric screening, fulfil the diagnostic criteria for HF. HF is a serious condition with significant morbidity and mortality. Dutch health care expenditures for HF are high (currently over half a billion Euros per year), and most of this expenditure is made in hospital care, underscoring the importance of prevention. Apart from the obesity itself, prevalence of other HF risk factors such as diabetes (20%) and hypertension (30%) is high in obese adults.

There is no active screening for HF or its risk factors in adults with obesity in the Netherlands. HF in people with obesity often remains undetected for a relatively long time, because symptoms are attributed to the obesity and not to possible HF. As a result, individuals seek help late for already advanced HF. Screening may reveal HF risk factors or a HF diagnosis. Early treatment initiation will improve prognosis, both in terms of quality of life and morbidity and mortality.

OBJECTIVES

Main research question: does active screening in primary care for HF or its risk factors in adults with obesity improve outcome, defined as a lower prevalence of a combined endpoint of left ventricular (LV) dysfunction and/or HF admission?

Hypothesis:

Primary care screening for early signs of HF in patients with obesity without known heart disease is effective, both in terms of clinical outcome measures and cost-effectiveness. Screening leads to a lower prevalence of LV dysfunction and HF after one year of follow-up due to initiation of treatment of HF and risk factors for HF identified at the time of screening.

Primary Objective:

To investigate whether active screening for early signs of HF and its risk factors in adults with obesity without known heart disease improves clinical outcome.

Sub-questions:

  1. What is the prevalence of undiscovered HF in adults with obesity participating in a combined lifestyle intervention (CLI) program, as identified at baseline by active screening?
  2. What is the prevalence of undiscovered risk factors for HF (e.g. hypertension, diabetes) in adults with obesity participating in a CLI program, as identified at baseline by active screening?
  3. What are, apart from the obesity itself, risk factors for having HF at baseline in adults with obesity participating in a CLI program?
  4. Does active screening for early signs of HF and its risk factors in adults with obesity without known heart disease participating in a CLI program lead to a better of quality of life as compared to standard care at 1 year follow-up?
  5. Does active screening for early signs of HF and its risk factors in adults with obesity without known heart disease participating in a CLI program lead to improvement of dyspnea (NYHA classification) at 1 year follow-up in screened patients with HF at the time of screening?
  6. Is the effect of the studied screening program driven by treatment of risk factors for HF in screened adults without HF at the time of screening, or by treatment of HF in adults with diagnosed HF at the time of screening?
  7. Is the studied screening program in adults with obesity cost-effective as compared to usual care of adults with obesity participating in a CLI program in The Netherlands?

STUDY DESIGN

SCOR(hf)E is an investigator driven, not blinded, randomized controlled superiority trial.

During two years, prospective inclusion of 468 subjects with obesity, aged 45 years and older, without a history of cardiac disease, will take place at 3 organizations of a CLI intervention. Subjects will be randomized 1:1 to either an active screening for HF or a continuation of standard care (a watchful waiting policy; these people will not undergo any investigations at baseline).

Subjects randomized to screening for HF will be evaluated using anamnesis, physical examination, an ECG, blood tests and an echocardiogram. Screening may reveal additional HF risk factors such as hypertension or diabetes that will be treated and followed according to guidelines. Patients will be given appropriate lifestyle advice. Patients with a HF diagnosis will be referred to a cardiologist and treated according to the guidelines.

The hypothesis of the study is that one year of treatment of the subset of screened patients with HF or HF risk factors identified at the time of screening, will lead to a lower prevalence of LV dysfunction and acute HF admissions (the main study endpoint) in the intervention group (the patients that underwent the HF screening) versus the control group. After one year, echocardiography will be performed in all subjects, both in the intervention and standard care group. Asymptomatic LV dysfunction (assessed with echocardiography) was chosen as a component of the primary endpoint as it reflects a heightened risk status, specifically to the later development of HF. Presence of HF will be defined as HF symptoms that have required an emergency hospital admission.

SAMPLE SIZE CALCULATION

Sample size calculation Follow-up time and sample size calculation are partly based on findings from the STOP-HF trial. This trial met its primary endpoint, showing a reduction of LV dysfunction and/or HF admissions from 8.7% to 5.3% by a screening program using B-type natriuretic peptide.

Estimated effect size:

The investigators will use global longitudinal strain (GLS), an echocardiographic parameter clearly more sensitive for LV dysfunction than the parameters used in the aforementioned STOP-HF trial. In our CARdiac Dysfunction In Obesity - Early Signs Evaluation (CARDIOBESE) study, 26% of patients with obesity without known HF ánd not fulfilling the criteria of LV dysfunction of STOP-HF, had significantly decreased GLS (currently used as a criterion for HF diagnosis). A conservative estimate would be that a year after screening, this proportion will be reduced to 19% due to the effect of treatment of patients with HF or risk factors for HF. Also, since the investigators can use improved treatment options developed during the last decade, the effect of the screening is expected to be larger than in STOP-HF.

In STOP-HF, acute HF admission occurred in 2.1% of the participants in the control group versus 1.0% of the intervention group.

Sample size calculation (two tailed, using α=0.05 and a power level of 80%) based on the aforementioned estimated effect size:

proportion of the primary endpoint in the control group 36.8% (26% (decreased GLS) + 8.7% (fulfilling the criteria of LV dysfunction of STOP-HF) + 2.1% (acute HF admissions)), proportion of the primary endpoint in the intervention group 24.0% (19% (decreased GLS) +4.0% (fulfilling the criteria of LV dysfunction of STOP-HF; effect of the screening is expected to be larger than in STOP-HF since the investigators can use improved treatment options) + 1.0% (acute HF admissions): sample size of 199 per group.

Withdrawal of study participation is expected to be maximal 5%. Therefore, the investigators will include 420 subjects.

RANDOMISATION, BLINDING AND TREATMENT ALLOCATION

Participants will be randomly assigned to a screening for HF or usual care (1:1). For allocation, a computer-generated block randomization sequence will be used, stratified by participating CLI practice. An independent physician from Franciscus Gasthuis \& Vlietland will extract the randomization schedule from an electronic randomization tool and send the codes in sealed, sequentially numbered, opaque envelopes to the participating practices.

STUDY PROCEDURES

Participants randomized to standard care will not undergo any tests related to the study at baseline.

Participants randomized to a screening for HF will receive an appointment at either the Franciscus Gasthuis \& Vlietland hospital or Star-shl diagnostic center, according to preference of the participant. Here, anamnesis and physical examination will be performed, blood samples will be taken and an ECG and echocardiogram will be acquired.

Diagnosis of HF will be based on the current guidelines. When HF is diagnosed, the patient will be referred to a cardiologist of the Franciscus Gasthuis \& Vlietland. When there are incidental findings, such as increased blood glucose or hypertension, patients will be referred to their general practitioner for follow-up and treatment when necessary.

After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached to assess the combined primary endpoint of LV dysfunction and/or an acute HF admission. Participants will be asked whether they have had an unplanned hospital admission for HF. If this is the case, information will be requested from the hospital in question. A joint panel consisting of three cardiologists will evaluate the findings and results of all diagnostic tests that took place during the admission. Adjudication of diagnoses by a panel of physicians is an accepted reference standard for the evaluation of HF, for which a true reference standard is lacking. In case the panel does not reach consensus, a majority decision will count. Also, in all participants an echocardiogram will be acquired, again in either the Franciscus Gasthuis \& Vlietland hospital or Star-shl diagnostic center. Finally, participants will be asked to fill-out the Health Related - Quality of Life (HR-QoL) with the EQ-5D-5L questionnaire.

STATISTICAL ANALYSIS

All analyses will be carried out on an intention-to-treat basis. The distributions of variables will be tested for normality by the Shapiro-Wilk test. The significance threshold will be defined as P \<0.05 and all tests are 2-sided.

Missing data will be handled using multiple imputation with chained equations with 10 imputations and 10 iterations per imputation. Predictive mean matching will be used for all variables.

Primary study parameter The difference in prevalence of LV dysfunction and HF between the intervention group and the control group will be analysed using logistic regression modelling.

Secondary study parameters

  • (subquestion 1 and 2) The prevalence of HF and/or undiscovered risk factors for HF as identified by active screening will be described as a percentage of the total screened population (the intervention group).
  • (subquestion 3) HF prevalence will be presented stratified by sex, age (tertiles), BMI (tertiles), waist circumference (tertiles), diabetes, hypertension and obstructive sleep apnea. Also, the investigators will provide descriptive statistics (parameters mentioned in the previous sentence) of the subjects in the intervention group with HF versus without HF at baseline. Differences between the groups in age, BMI and waist circumference will be tested using independent t-tests in case of normal distribution or Mann-Whitney-U tests in case of non-normality. Differences in % male, diabetes, hypertension and obstructive sleep apnea will be tested with Chi-square tests.
  • (subquestion 4) Findings of the HR-QoL questionnaire will be compared between the intervention and standard care groups, using independent t-test or Mann-Whitney-U test for the total scores, and Chi square tests for the subscales.
  • (subquestion 5) The Chi Square test will be used in screened patients with HF at the time of screening, to compare NYHA classification at baseline and follow-up.
03

Conditions studied

  • Obesity
  • Heart Failure

Keywords

  • Screening
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥45 year
  • ≥30 kg/m2
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Known cardiac disease (determined by asking the patient and by assessment of the available patient files).
  • Treatment with weight-reducing medication.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Participants randomized to HF screening

    Active screening on HF and its risk factors, using anamnesis, physical examination, an ECG, blood tests and an echocardiogram. After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire.

    Diagnostic Test: Screening for heart failure

  • No intervention
    Participants randomized to standard care

    Participants randomized to standard care will not undergo any tests related to the study at baseline. After 1 year follow-up, both participants randomized to standard care and to screening for HF will be approached. Participants will be asked whether they have had an unplanned hospital admission for HF. Also, in all participants an echocardiogram will be acquired. Finally, participants will be asked to fill-out the HR-QoL with the EQ-5D-5L questionnaire.

Interventions

  • Diagnostic testScreening for heart failure

    • Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee. • ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist. • Echocardiography: A standard full echocardiogram will be acquired by a trained employee. • Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage. • EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'.

06

What researchers measure

Primary outcomes

  1. Number of participants with a combined endpoint of left ventricular dysfunction and/or heart failure

    Asymptomatic left ventricular dysfunction (assessed with echocardiography) was chosen as a component of the primary endpoint as it reflects a heightened risk status, specifically to the later development of heart failure. Left ventricular dysfunction is defined as a left ventricular ejection fraction \<50%, a ratio of mitral peak velocity of early filling to early diastolic mitral annular velocity greater than 15, or global longitudinal strain \<16%. Presence of heart failure will be defined as HF symptoms requiring emergency hospital admission.

    Time frame: 1 year

Secondary outcomes

  1. Prevalence of HF as identified by active screening

    HF diagnosis as defined in current guidelines. Diagnostic criteria will be optimized for subjects with obesity in accordance with current insights / medical literature.

    Time frame: Baseline

  2. Prevalence of undiscovered risk factors for HF as identified by active screening

    For example diabetes or hypertension

    Time frame: Baseline

  3. EQ-5D-5L questionaire

    The EuroQol 5 dimensions 5 levels (EQ-5D-5L) descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels, with the highest level being related to the most problems: 1. no problems 2. slight problems 3. moderate problems 4. severe problems 5. extreme problems The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The Dutch tariff will be used to generate index scores (utility values) based on EQ-5D-5L outcomes.

    Time frame: 1 year

  4. Self-rated health on a Visual Analogue Scale (EQ VAS)

    The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement

    Time frame: 1 year

  5. Effect of HF treatment on symptoms in screened patients with HF at the time of screening

    Dyspnea will be scored according to the New York Heart Association (NYHA) classification, the most commonly used classification system for HF symptoms. The classification places patients in one of four categories based on limitations of physical activity: I. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II. Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III. Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV. Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 33 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Nov 18, 2023
StartActual
Feb 26, 2024
Primary completionEst.
Dec 8, 2026
CompletionEst.
Dec 8, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06137261
Lead sponsor
Franciscus Gasthuis
Collaborators
Erasmus Medical Center, Star-shl, De Leefstijlkliniek, Leefstijl Centrum Rotterdam, Voedingsadvies Broer, Biotronik SE & Co. KG, Boehringer Ingelheim, Sanofi, Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Feb 26, 2024
Primary completion
Dec 8, 2026 (estimated)
Completion
Dec 8, 2026 (estimated)
Last update
Sep 3, 2026

Study contacts

Bas M van Dalen, Dr.
principal investigator · Franciscus Gasthuis & Vlietland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion